Rocket One Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new generation therapies designed to address unmet medical needs. The company's development pipeline features drug candidates targeting various conditions across oncology, dermatology, allergy, and neurology. Key pipeline assets include HT-001, a topical formulation for treating skin toxicities resulting from cancer therapies; HT-KIT, a targeted therapeutic for mast cell-derived neoplasms and anaphylaxis; and HT-ALZ, an asset aimed at treating and preventing Alzheimer’s disease and other neuroinflammatory conditions. Additional programs comprise BioLexa for atopic dermatitis, HT-004 for asthma and allergies, and HT-VA for obesity. The company creates these therapies primarily for patients requiring specialized interventions.

The company operates in the United States and has conducted clinical activities in Australia, while securing regulatory authorizations to expand trials into European nations including Spain, Poland, and Hungary. Hoth Therapeutics maintains its principal executive offices in Hoboken, New Jersey.

Summary of the business section of Rocket One's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 26, 2025, we employed a total of 2 full-time employees, 3 employee consultants, and 1 part-time employee.”